Synthesis of liraglutide

Patent metadata

Field	Value
Publication number	US-11066439-B2
Application number	US-201716468190-A
Country	US
Kind code	B2
Filing date	Dec 9, 2017
Priority date	Dec 10, 2016
Publication date	Jul 20, 2021
Grant date	Jul 20, 2021

Abstract

The present invention relates to the efficient solid-phase synthesis of liraglutide represented by Formula-I. The present invention relates to an efficient process for the preparation of liraglutide by sequential coupling employing solid phase approach. It involves sequential coupling of protected amino acids to prepare backbone of liraglutide and upon completion of linear sequence, synthesis was extended from lysine side chain by adding γ-glutamic acid and palmitic acid, followed by removal of protective groups, cleavage of the peptide from solid support and purification of crude liraglutide obtained. The present invention also involves the usage of inorganic salts during the coupling, wash with HOBt in DMF solution after Fmoc-deprotection step to suppress the aggregation of peptides and ensure reactions are going for completion, and thus avoid deletion sequences and improve the process yield.

First claim

The invention claimed is:

1. A process for the preparation of liraglutide comprising the steps of,
a) loading of C-terminal glycine to a resin solid-phase support in the presence of a coupling agent;
b) capping of the unreacted functional sites;
c) sequential coupling of N α - and side chain protected amino acids to prepare the backbone of liraglutide, in the presence of a coupling agent and an inorganic salt;
d) deprotecting the side chain protecting group of lysine;
e) coupling of glutamic acid and palmitic acid to the side chain of lysine in the presence of a coupling agent and an inorganic salt; and
f) obtaining crude liraglutide by removal of protective groups and cleavage of peptide from the resin,
wherein the process comprises coupling of amino acids 9 to 13 at a temperature range of 30-45° C.,
wherein the inorganic salt is present in a catalytic amount and is selected from the group consisting of magnesium chloride, zinc chloride and copper chloride,
wherein step (c) comprises deprotection of the Fmoc group of each loaded amino acid using piperidine in DMF or a piperidine/DBU/DMF mixture, wherein after each Fmoc deprotection step there is a washing step using HOBt in DMF and deprotection of the methyltrityl protecting group of lysine.

2. A process for the preparation of liraglutide comprising the steps of,
a) coupling of N α -Fmoc-protected glycine (Fmoc-Gly-OH) to a resin solid-phase support in the presence of a coupling agent;
b) sequential coupling of N α - and side chain protected amino acids to prepare backbone of liraglutide, in the presence of a coupling agent and an inorganic salt;
c) deprotecting of the side chain protecting group of lysine;
d) coupling of palmitoyl-glutamic acid (Pal-Glu-O t Bu) side chain to the side chain of lysine in the presence of a coupling agent and an inorganic salt; and
e) obtaining crude liraglutide by removal of protective groups and cleavage of peptide from the resin,
wherein, the process comprises coupling of amino acids 9 to 13 at a temperature range of 30-45° C.,
wherein the inorganic salt is present in a catalytic amount and is selected from the group consisting of magnesium chloride, zinc chloride and copper chloride,
wherein step (c) comprises deprotection of the Fmoc group of each loaded amino acid using piperidine in DMF or a piperidine/DBU/DMF mixture, wherein after each Fmoc deprotection step there is a washing step using HOBt in DMF and deprotection of the methyltrityl protecting group of lysine.

3. The process of claim 1 which involves coupling agents selected from the group consisting of HBTU, COMU, DEPBT, DIC, and any combination thereof.

4. The process of claim 1 which involves coupling additives selected from the group consisting of oxymapure, HOBt, and any combination thereof.

5. The process of claim 1 , wherein coupling of Boc-Histidine uses a coupling agent mixture selected from the group consisting of HBTU-oxyma pure, COMU-oxyma pure, DEPBT-oxyma pure, and DIC-oxyma pure.

6. The process of claim 5 , wherein the coupling of Boc-Histidine uses DEPBT-oxyma pure.

7. The process of claim 1 comprising, deprotection of a Methyltrityl protecting group of lysine using HFIP/TES/TFE/MDC.

8. The process of claim 1 , further comprising purifying crude liraglutide.

9. The process of claim 1 , wherein capping of the unreacted functional sites is carried out using acetic anhydride and organic base, and coupling of glutamic acid and palmitic acid to the side chain of lysine is carried out in a sequential manner.

10. The process of claim 2 , further comprising purifying crude liraglutide.

11. The process of claim 2 , wherein deprotection of the side chain protecting group of lysine comprises deprotection of the side chain methyltrityl protecting group of lysine using TFA in dichloromethane, and subsequent coupling of palmitoyl-glutamic acid (Pal-Glu-OtBu) side chain to the deprotected side chain of lysine in the presence of a coupling agent selected from HBTU, COMU, DEPBT, and DIC and an additive selected from oxymapure and HOBt, or a combination of coupling agents/additives thereof, and an inorganic salt.

12. The process of claim 2 , wherein deprotection of the methyltrityl protecting group of lysine comprises using HFIP/TES/TFE/MDC, and/or wherein coupling of protected glutamic acid and palmitic acid is carried out in sequential manner to the side chain of lysine in the presence of coupling agent and an inorganic salt.

13. The process of claim 1 , wherein the catalytic amount ranges from 0.01 to 0.1 eq.

14. The process of claim 2 , wherein the catalytic amount ranges from 0.01 to 0.1 eq.

Assignees

• Biocon Ltd

Inventors

• Ganga Ramu Vasanthakumar
• Patil Nitin
• Charyulu Palle Venkata Raghavendra
• Jasmine Castelino Roopa
• Machani Rambabu
• Suvarna Deepa Shankar

Classifications

• Y02P20/55

  Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups · CPC title

• C07K14/605 Primary

  Glucagons · CPC title

• C07K1/10 Primary

  using coupling agents {(C07K1/006 takes precedence)} · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C07K1/1077

  by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids · CPC title